Comparative Pharmacology
Head-to-head clinical analysis: SANCTURA versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SANCTURA versus VESICARE LS.
SANCTURA vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trospium chloride is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, thereby reducing detrusor muscle contractions and increasing bladder capacity.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
20 mg orally twice daily, with or without food. Maximum dose 20 mg twice daily.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12–20 hours in healthy adults, allowing twice-daily dosing.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Primarily renal (approximately 60% as unchanged drug and metabolites); biliary/fecal elimination accounts for ~30%.
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category C
Category C
Anticholinergic
Anticholinergic